Business Context and Reporting Period
This Form 8-K Current Report was filed by Calyxt, Inc. on August 24, 2018, covering events occurring on August 21 and August 22, 2018. The filing details significant changes to the company's executive leadership and Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Executive Leadership Change: Federico Tripodi departed the company to pursue other opportunities. Yves Ribeill, Ph.D., was appointed as Interim Chief Executive Officer, effective August 22, 2018.
- Board Appointment: Jonathan Fassberg was appointed as a member of the Board of Directors and the Audit Committee, effective immediately. The Board determined Mr. Fassberg is an independent director and an "audit committee financial expert."
Management Commentary, Compensation, and Risks
Interim CEO Compensation (Dr. Yves Ribeill):
- Base Salary: $400,000 annually.
- Performance Bonus: Target value of 60% of base salary, prorated based on employment duration and performance goals.
- Equity Awards: 180,000 stock options and 60,000 restricted stock units. Vesting is scheduled in three equal tranches on January 1, 2019, January 1, 2020, and January 1, 2021.
- Term: Employment ends on the earlier of August 21, 2019, or the appointment of a permanent CEO.
- Benefits: Includes customary executive benefits, vacation, expense reimbursement, and accommodation costs in Minneapolis, Minnesota.
Board Member Compensation (Mr. Jonathan Fassberg):
- Compensation will be in accordance with standard arrangements for non-employee directors.
- Received an indemnification agreement.
Risks and Contingencies: The filing notes customary non-solicitation, non-compete, intellectual property, and confidentiality provisions in the CEO's employment agreement. No other material transactions or family relationships were disclosed.
Investor Verification Checklist
- Verify the departure date and reason for Federico Tripodi's exit.
- Confirm the vesting schedule and valuation of the 180,000 stock options and 60,000 RSUs granted to Dr. Ribeill.
- Review the specific performance goals tied to Dr. Ribeill's 60% target bonus.
- Assess the timeline for the Board's search for a permanent CEO to determine the duration of the interim arrangement.
- Confirm Mr. Fassberg's specific compensation package details as a non-employee director.